-
Nanfang pharmaceutical a new type of new targeted nano Paclitaxel injection (Xinsu) is expected to complete preclinical research in 2017
Time of Update: 2020-04-03
"Xinsu" is a new anti-cancer drug developed by Nanfang pharmaceutical last year R & D is divided into six stages, and now it has entered the third stage " On May 10, Li Yong, deputy general manager of
-
Enhua pharmaceutical heavy new drug Remifentanil Hydrochloride for Injection approval completed
Time of Update: 2020-04-03
According to the information on the website of CFDA on October 13, the review status of remifentanil hydrochloride for injection, a heavy new drug of Enhua Pharmaceutical Co., Ltd., was changed to "ap
-
Announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on withdrawal of application for production of faropenem sodium tablets by holding subsidiary
Time of Update: 2020-04-03
Securities code: 600196 stock abbreviation: Fosun Pharmaceutical No.: Lin 2015-101 bond Code: 122136 bond abbreviation: 11 Fosun bond Shanghai Fosun Pharmaceutical (Group) Co., Ltd announcement on wit
-
Chinese and American researchers found that the combination of diphosphonic acid and rapamycin can treat drug-resistant lung cancer
Time of Update: 2020-04-03
Chinese and American researchers said Tuesday they have found a promising treatment for drug-resistant lung cancer The results showed that the survival time of mice with cancer could be doubled by usi
-
Hanyu pharmaceutical's new drug enkephalin and injection enter the site for inspection
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 11, Hanyu pharmaceutical's heavyweight new drug, enkephalin and enkephalin injection, has entered the site for inspec
-
Inventory (1): number of clinical approval of drugs in the first half of 2013-2015
Time of Update: 2020-04-03
In the environment of the growth of biological drugs and the shrinking of the registration of imported drugs, what is the situation of drug approval in China? According to insight database statistics,
-
The phase report of "preclinical research on new antitumor drugs of Staphylococcus aureus enterotoxin C2 modified protein" was held
Time of Update: 2020-04-03
On December 9, the project of "preclinical research on new antitumor drugs of staphylococcal enterotoxin C2 modified protein", a major national science and technology project during the 12th Five Year
-
Yikoning, the world's first hepatitis E vaccine developed in China, will go on the market in October
Time of Update: 2020-04-03
Behind the development of the world's first hepatitis E vaccine China is a high prevalence area of hepatitis E, but the public's understanding of hepatitis E is relatively low, and the harm of hepatit
-
Transforming medicine to develop personalized medicine
Time of Update: 2020-04-03
"Under the trend of personalized medical treatment, the new drugs in the future will no longer be a" blockbuster "with more than one billion dollars, and personalized research and development for the
-
Jiahe biology cooperates with American sharp company to develop innovative biological medicine ryi-008 for tumor and autoimmunity
Time of Update: 2020-04-03
Ryi-008 is an innovative monoclonal antibody against IL-6, which has unique pharmacological properties and is expected to create a new treatment for related diseases This is an important milestone for
-
Mb07133, a new targeted drug of Xi'an Xintong drug, class 1.1 liver cancer, obtained clinical approval
Time of Update: 2020-04-03
Mb07133, a new liver cancer targeting drug developed by Xi'an Xintong Pharmaceutical Research Co., Ltd., has recently been approved by the State Food and Drug Administration for clinical research, whi
-
Xi'an Xintong 1.1 liver cancer targeting new drug "mb07133 for injection" obtained clinical approval
Time of Update: 2020-04-03
Recently, with the approval of the State Food and drug administration, the new drug mb07133 for injection, a class 1.1 liver cancer targeting drug declared by Xi'an Xintong Pharmaceutical Research Co.
-
Jingxin Pharmaceutical Co., Ltd. and xinlitai entered the three in one review on the same day
Time of Update: 2020-04-03
Levetiracetam is a pyrrolidone derivative Because of its high therapeutic index, mild adverse reactions and good tolerance, it is the most widely used new antiepileptic drug In China, only the origina
-
Review of drugs accepted by CDE in April 2014 (2)
Time of Update: 2020-04-03
In April 2014, CDE accepted 63 clinical applications for new drugs of 2-5 categories of chemicals, including 9 anti-tumor drugs, 7 respiratory drugs, 6 digestive system drugs, 6 blood and hematopoieti
-
Cetabine, a 6-class generic of Qilu pharmaceutical, has been approved for production
Time of Update: 2020-04-03
On May 12, the raw materials and injection land of dixitabin developed by Qilu pharmaceutical obtained the production approval issued by the State Food and drug administration Desetabine is a demethyl
-
Green leaf pharmaceutical new prostate cancer drug approved by FDA
Time of Update: 2020-04-03
Green leaf Pharmaceutical (02186 HK) announced that the group's in-process product, geserelin acetate sustained-release microspheres for injection (ly01005), has been approved by the U.S Food and Drug
-
Additional clinical approval documents for the old 6 types of imitation of agliptin
Time of Update: 2020-04-03
Approval document for clinical trial of drugs Jian Kang Yuan (SH: 600380): Announcement on the approval document for clinical trial of drugs obtained by coastal pharmaceutical, a wholly-owned subsidia
-
Tonghua Dongbao third generation insulin analogue aspart insulin injection obtained the approval of clinical trial
Time of Update: 2020-04-03
Aspartic insulin is the third generation of insulin treatment drug, which belongs to insulin analogue This is the second insulin analogue obtained by Tonghua Dongbao after last year's clinical applica
-
Xinlitai, Jingxin pharmaceutical and Chongqing shenghuaxi pharmaceutical realized the first batch of domestic imitations of zuoeilacetan
Time of Update: 2020-04-03
According to the information on the website of CFDA on June 9, the 3.1 chemical medicine zuoxiracetam APIs and tablets declared for production by xinlitai, Jingxin pharmaceutical and Chongqing shenghu
-
Fosun Pharmaceutical's US $83.5 million large transaction layout in the domestic kidney disease Market
Time of Update: 2020-04-03
Fosun Pharmaceutical issued a notice on February 15, saying that its holding subsidiary Shanghai kaimao biomedical Co., Ltd (kaimao bio) signed an agreement with Korean genexine company to obtain the
